• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

    166.76 -0.58 (-0.35%)
    Streaming Delayed Price Updated: 11:13 AM EST, Jan 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Belite Bio, Inc - American Depositary Shares

    < Previous 1 2 3 4 Next >
    News headline image
    Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
    From Belite Bio, Inc
    Via GlobeNewswire
    InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
    Via Investor Brand Network
    News headline image
    Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
    Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
    From Virtual Investor Conferences; Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in the 2025 Maxim Growth Summit
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in Three Upcoming Investor Conferences
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces Registered Direct Offering of $15 Million
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
    Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Belite Bio to Participate in Four Upcoming Investor Conferences
    From Belite Bio, Inc
    Via GlobeNewswire
    News headline image
    UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
    From Virtual Investor Conferences
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.